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A COMPARISON OF THE RATE OF ARTERIOSCLEROSIS IN PATIENTS WITH 
THE MARFAN SYNDROME AND THE GENERAL POPULATION. Biren P. Modi 
and John A. Elefteriades. Section of Cardiothoracic Surgery, Department of Surgery, 
Yale University School of Medicine, New Haven, CT. 
The purpose of this study was to determine the prevalence of arteriosclerosis in patients 
with the Marfan syndrome in comparison to control individuals from the general 
population. The study arm consisted of 8 patients with Marfan syndrome who had 
available preoperative computed tomography (CT) scans of the chest without intravenous 
contrast. The control arm consisted of 8 age and gender matched patients who also had 
available CT scans of the chest. The CT scans were evaluated for the presence of 
calcium in the thoracic aorta and the coronary arteries using a semi-quantitative scale 
score of 0-3 for each artery. For all patients, a thorough chart review was conducted to 
search for body mass index and any history of hypertension, hypercholesterolemia, 
diabetes, prior stroke, prior myocardial infarction, or smoking. Though the differences 
were not significant, the Marfan group was younger, leaner, more likely to qualify as 
hypertensive due to beta-blocker administration, and less likely to be diabetic. The mean 
aortic calcium scores for Marfan patients and control patients were 0.000 and 0.125, 
respectively (p=0.5). The mean coronary calcium scores for Marfan patients and control 
patients were 0.000 and 0.125, respectively (p=0.5). These results suggest that some 
trends do exist which could indicate that and explain why Marfan patients have less 
advanced arteriosclerosis. Future studies will bear out these trends. 
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Background on Arteriosclerosis 
Definition 
Arteriosclerosis, literally translated as the hardening of arteries, is a broad term 
encompassing several disease states within the arterial circulation which have in common 
the thickening and loss of elasticity of the arterial wall. The majority of cases of 
arteriosclerosis consist of atherosclerosis, the presence of atheromatous plaques within 
the vessel walls of large elastic arteries (e.g., aorta) and medium-sized muscular arteries 
(e.g., coronary arteries) (1-3). In addition, arteriosclerosis may include Monckeberg 
calcification of the arterial media, which can occur in conjunction with advanced 
atherosclerosis, and arteriolosclerosis, which is a similar process involving the smaller 
arterioles of the arterial system (2). The most clinically significant, and the pattern which 
is under discussion in this study, is atherosclerosis. 
Pathophysiology 
There has been a tremendous growth in the understanding of the mechanisms 
underlying atherosclerosis in the past decades, but many uncertainties still exist. It is 
now generally accepted that atherosclerosis is a dynamic process which evolves through 
the interplay of many factors. These factors include the endothelial and smooth muscle 
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cells of the arterial wall, inflammatory cells and molecular mediators from the 
circulation, and the extracellular matrix. The following is a brief description of the 
macroscopic evolution of atherosclerosis and the microscopic players in the process. 
Atherosclerosis is a generalized process involving many arterial territories, 
including the coronary circulation, the head vessels, the aorta, and the peripheral 
circulation (1, 4-7). This fact is useful in understanding the pathophysiology of the 
process as well as in applying techniques for molecular study, imaging, and therapy. 
Since the risk factors for atherosclerotic disease are the same regardless of location, it is a 
natural extension that the mechanisms of pathogenesis are similar in all vascular 
territories and that treatment or prevention for one clinical manifestation would likewise 
treat and prevent all atherosclerotic disease (4). In descending order, the arteries most 
affected by atherosclerosis are the abdominal aorta, the coronary arteries, the popliteal 
arteries, the descending thoracic aorta, the internal carotid arteries, and the arteries of the 
circle of Willis (2). In all of these vessels, there exists a characteristic pattern of 
distribution of atherosclerotic plaques, with most lesions located at the ostia of branches 
(2, 8). 
Atheromas, or atherosclerotic plaques, consist of varying proportions of cells 
(e.g., smooth muscle cells, macrophages, and leukocytes), connective tissue extracellular 
matrix (e.g., collagen, elastins, and proteoglycans), and lipid deposits (e.g., intracellular 
and extracellular cholesterol or cholesterol esters) (1-3). These components collect 
within the intima of the arterial wall, leading to intimal thickening followed sequentially 
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by development of a fatty streak, atheroma, and fibrous plaque (3, 7). In addition, as they 
advance in age and complexity, atheromas develop a fibrous cap composed of cells and 
dense connective tissue, all within the intima and covered by the endothelium of the 
artery. 
This process of atheroma evolution is believed to begin very early in life as fatty 
dots, less than 1mm in diameter, which then coalesce to form fatty streaks. These streaks 
form the precursors of fully developed atherosclerotic plaques, though the exact 
mechanisms are not fully known. Evidence for this relationship comes from autopsy data 
which shows that fatty streaks, which are nearly universal in children, occur at the same 
anatomic locations that are later prone to have plaques. In addition, as children grow 
older and develop more plaques, the number of fatty streaks decreases, suggesting that 
they may be evolving into plaques. Risk factors known to be associated with 
atherosclerosis are also associated with fatty streaks early in life. It is important to note, 
however, that though atherosclerotic plaques may develop from fatty streaks, not all fatty 
streaks will develop into plaques or more advanced lesions (2, 9). 
As these fatty streaks progress, they become atheromas, with varying amounts of 
cells, lipids, and extracellular matrix. This progression is described by the American 
Heart Association classification of atherosclerotic lesions (Table 1). As these atheromas 
evolve and become more numerous, they can lead to a number of complications. 
Possible complications include occlusion of smaller arteries, distal embolization, 
hemorrhage into the plaque, and destruction of larger arteries with invasion of the arterial 
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media. This latter complication can cause disruption of normal wall mechanical 
properties leading to thrombosis, aneurysm, or rupture. Perhaps the most clinically 
important complication is focal rupture or ulceration of the plaque with precipitation of 
thrombosis of the vessel. A “complicated” atherosclerotic plaque can also possess 
variations from the generic structure. These variations include calcification, which can 
be used as a marker for advanced disease as described below (2). 
Criteria for American Heart Association Lesion Classification System and Correspondence Vlth 
Classification of Gross Arterial Specimens* 








Normal artery with or without adaptive 
intimal thickening; no hold 
Isolated MFCs containing lipid; no extracellular 
lipid; variable adaptive intimal thickening 
grossly with lipid staining 
Numerous MFCs, often in layers, with fine 
particles of extracellular lie id; no distinct 
pools of extracellular lipid: variable adaptive 
intimal thickening 
Numerous MFCs with i pools of extracellular 
lipid; no well-defined core of 
extraceltular lipid 
Numerous MFCs plus well-defined core of 
extracellular lipid, but with luminal 
surface covered by relatively normal intima 
Numerous MFCs, well-defined core or multiple 
cores of extracellular lipid, plus 
reactive fibrotic cap, vascularization, 
or calcium 
All of the above plus surface defect, hematoma, 
hemorrhage, or thrombosis 
Normal tissue 
Initial atherosclerotic lesion, sometimes 
visible grossly with lipid staining 
Fatty streak, visible grossly with 
III staining 
Fatty plaque, raised fatty streak, 
intermediate lesion, or transitional lesion 
Atheroma, fibrous plaque, or raised lesion 
Fibroartherema, fibrous plaque, or raised 
lesion 
Complicated lesion 
MFC indicates macrophage foam cell; AHA, American Heart Association 
Table 1. American Heart Association atherosclerotic lesion classification system. 
(Reproduced from Rackley C.E. 2001. Pathogenesis of atherosclerosis. In UpToDate 
ed. 9.3, www.uptodate.com) 
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The clinical importance of atherosclerosis depends upon the chronic and acute 
impedance of blood flow via stenosis of the vessel lumen or via distal embolization. The 
original response of the arterial vessel to the atherosclerotic plaque is positive 
remodeling, a process which preserves the arterial lumen by outward growth of the 
vessel. As the capacity of the vessel to remodel outward is exceeded, the process of 
negative remodeling, which encroaches on the vessel lumen, begins to interfere with 
normal blood flow (3, 7). Thus, a plaque is quite large before it starts to impinge on the 
vessel lumen. Positive and negative remodeling are depicted in Figure 1. Plaque growth 
can occur via inclusion of more cells and extracellular matrix as well as by repetitive 
cycles of superficial plaque erosion with subsequent thrombosis and healing. The 
manifestations of atherosclerotic disease generally affect the coronary, cerebral, lower 
extremity and intestinal vasculature. As the plaque grows larger, over the course of many 
decades, the plaque may cause decreased blood flow during times of increased demand, 
resulting in symptoms such as angina pectoris or claudication. However, in many cases, 
acute coronary events such as myocardial infarction occur without prior symptoms, with 
the likely mechanism being acute rupture of the fibrous cap or erosion into the plaque 
with subsequent thrombus formation occluding the vessel lumen. In these cases, the 
disease is often deadly. For example, 1 out of every 3 initial coronary attacks is fatal (3- 
4). Distal embolization of plaque or thrombus can also result in clinical symptoms such 
as transient ischemic attacks, stroke, or intestinal ischemia. 
Figure 1 (on following page). A schematic life history of the atherosclerotic plaque 
demonstrating positive and negative remodeling. (Reproduced from Libby P. 2001. The 
vascular biology of atherosclerosis. In Heart Disease: A Textbook of Cardiovascular 




Molecular and Cellular Biology 
The molecular pathology and pathogenesis of these lesions is summarized in the 
“response to injury” hypothesis, which states that atherosclerosis is a chronic 
inflammatory process within the arterial wall in response to injury to the endothelium (2). 
The hypothesis consists of the following steps: focal chronic injury to the endothelium 
with resultant endothelial dysfunction, insudation and modification of lipoproteins, 
immigration of monocytes and leukocytes with subsequent conversion of monocytes into 
macrophages and foam cells, release of molecular factors causing migration of smooth 
muscle cells from the media into the intima, proliferation of smooth muscle cells and 
elaboration of extracellular matrix, and continued accumulation of lipids both 
intracellularly, within macrophages and smooth muscle cells, and extracellularly. These 
steps and their molecular and cellular participants are described in detail below and 
summarized in Table 2 and Figure 2. 
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Event Mechanism Molecular Players 
1. Chronic endothelial 
injury causing increased 
endothelial permeability 











—Foam cell formation 
—Direct toxicity 
Oxidized LDL, superoxide, 
scavenger receptor 
3. Recruitment of 
monocytes with formation 
of foam cells 
—Chemotaxis and cell 
adhesion 
—Elaboration of cytokines, 
chemokines and growth 
factors leading to growth of 
lesion and immigration of 
smooth muscle cells and 
leukocytes 
IL-1, TNFa, MCP-1 
4. Immigration and 
proliferation of smooth 
muscle cells 




PDGF, FGF, TGFa, TGFp, 
collagen, elastin, 
proteoglycans 









proteins, IL-6, estradiol 
Table 2. A summary of the steps in the “response to injury” hypothesis and some of the 
key molecular mediators. (Abbreviations: ICAM-l=intercellular adhesion molecule-1, 
VCAM-l=vascular cell adhesion molecule-1, E-selectin=endothelial selectin, P- 
selectin=platelet selectin, LDL=low density lipoprotein, IL=interleukin, TNFa=tumor 
necrosis factor-a, MCP-l=monocyte chemoattractant protein-1, PDGF=platelet derived 
growth factor, FGF=fibroblast growth factor, TGF=transforming growth factor, Gla- 











• Hemodynamic factors 
• T oxins 
• Viruses 
• Immune reactions, 
I 
Response to injury 
I 
Endothelial dysfunction 




3. Smooth muscle 
emigration from media 
to intima. Macrophage 
activation.. 
4. Macrophages and \ 




Figure 2 (on preceding page). Schematic showing steps in the “response to injury” 
hypothesis. (Reproduced from Schoen F.J., and Cotran R.S. 1999. Blood vessels. In 
Robbins Pathologic Basis of Disease. R. Cotran, V. Kumar, and T. Collins, editors. 
Philadelphia: W.B. Saunders Company. 493-541) 
The process of atherosclerosis in this model begins with endothelial dysfunction 
resulting from chronic injury to focal areas of endothelium. The dysfunction is manifest 
in increased endothelial permeability and enhanced leukocyte adhesion through 
endothelial cell expression of intercellular adhesion molecules of the immunoglobulin 
superfamily (e.g., intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1)) and the selectins (e.g., endothelial selectin (E-selectin) and 
platelet selectin (P-selectin)) (2-3). This dysfunction is distinct from normal arterial 
endothelium, which is resistant to adhesive interactions with circulating cells, and from 
inflamed tissue, in which the process of inflammatory cell recruitment occurs in the post¬ 
capillary venule, not the artery or arteriole (3). Many initiating factors for endothelial 
injury have been suggested, including endotoxins and infectious agents, hypoxia, 
products contained in cigarette smoke, and endothelial toxins such as homocysteine (2, 
7), but the concept of endothelial injury in this hypothesis relies on two main mechanisms 
of injury. One stems from hemodynamic disturbances while the other stems from the 
adverse effects of hypercholesterolemia. The finding that most atherosclerotic plaques in 
large arteries occur in the area of ostia to branch arteries is well defined and lends support 
to the first mechanism (2, 8). In addition, it is known that disturbed flow induces 
proatherogenic activities in the endothelium, including the adhesion molecules mentioned 
above, while smooth laminar flow actually induces antiatherogenic, or atheroprotective, 
gene products such as the antioxidant superoxide dismutase (2-3). 
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Hyperlipidemia, specifically hypercholesterolemia, also contributes to 
atherogenesis. The mechanisms underlying this activity include production of oxygen 
free radicals leading to endothelial injury and insudation of lipoproteins within the intima 
at sites of increased endothelial permeability, thus beginning the formation of the fatty 
streak. This leads to the modification of these lipoproteins via oxidation by oxygen free 
radicals (2-3). These modified lipoproteins are then ingested via the scavenger receptor 
of macrophages which, unlike the normal LDL receptor, is able to ingest modified LDL 
(3). This process leads to foam cell formation, chemotaxis of circulating monocytes, 
monocyte adhesion, recruitment and retention within the lesion, release of cytokines and 
growth factors, and direct injury to endothelial and smooth muscle cells (2). It is at this 
level that the beneficial effects of antioxidants such as vitamin E and betacarotene may be 
manifest (7). 
In conjunction with the role of lipoproteins, circulating monocytes are recruited to 
the area of the lesion via the expression of the specific adhesion molecules discussed 
above. The selectins contribute to the saltatory motion of circulating cells while the 
immunoglobulin family molecules contribute to binding of the cells to the endothelium. 
Chemotaxis due to oxidized LDL and the resultant expressed cytokines then leads to the 
diapedesis of these cells into the intima, the ingestion of oxidized LDL via the scavenger 
receptor, and the formation of foam cells (2-3). These cells now play a significant role in 
the progression of the plaque. They release the important cytokines interleukin-1 (IL-1) 
and tumor necrosis factor-alpha (TNF-a), and the chemokine monocyte chemoattractant 
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protein-1 (MCP-1), all of which further the recruitment of monocytes and leukocytes. In 
addition, they elaborate chemokines and growth factors which lead to the migration of 
smooth muscle cells from the media into the intima and their subsequent proliferation (2- 
3). With the continuation of these processes through continued endothelial injury and 
persistent hypercholesterolemia, these lesions grow and aggregate, forming fatty streaks. 
If the hypercholesterolemia is treated, the lesions up to this point may regress without 
progression (2-3). 
The next steps in the progression of the atherosclerotic lesion are important to the 
conversion from fatty streak to mature atheroma and subsequent complicated plaque (2). 
As smooth muscle cells, normally quiescent cells within the media of the arterial wall, 
migrate into the intima and proliferate, they synthesize an extracellular matrix composed 
of collagen, elastin, and glycoproteins (2-3). This process is governed by the cytokines 
and growth factors elaborated by the adherent platelets and leukocytes, macrophages and 
foam cells, endothelial cells, and the smooth muscle cells themselves. These factors 
include platelet derived growth factor (PDGF), fibroblast growth factor (FGF), and 
transforming growth factor-alpha (TGF-a) and beta (TGF-(3) (2-3). 
Progression of the plaques from these early lesions involves maturation of the 
core from a simple aggregation of foam cells derived from macrophages and smooth 
muscle cells to a cellular-fatty atheroma consisting of surviving foam cells, dead cells 
with cellular debris and extracellular lipids, and deposited collagen and proteoglycans. In 
addition, the connective tissue on the intimal aspect is organized into a fibrous cap. As 
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they age, these fibrofatty atheromas can undergo further connective tissue proliferation to 
become fibrous plaques. The larger plaques, like neoplasms, also stimulate adjacent 
angiogenesis through mediators such as vascular endothelial growth factor (VEGF) (3). 
In addition, these lesions can progress to “complicated” plaques as described in the 
section on pathogenesis. For example, the important event of rupture and thrombus 
formation is thought to originate with the digestion of the extracellular matrix and fibrous 
cap by matrix metalloproteinases released by resident macrophages (1,3, 9). 
Another feature, calcification of the plaque, is of particular interest to this study 
and is therefore described here in some detail. One of the modifications which defines a 
plaque as “complicated” is mineralization with calcium. The process is likely a dynamic 
interaction of cells and mediators with regulation similar to the process of bone formation 
(3, 9, 10). Important mediators of this regulation are intercellular messenger molecules, 
such as interleukin-6 (IL-6) and estradiol (11). In addition, the plaques contain bone 
morphogenetic protein-2a, a potent factor influencing osteoblast differentiation, and often 
contain fully formed bone tissue, including marrow (9, 12). Other factors involved in the 
process are osteopontin, osteonectin, and osteocalcin, all known to be involved in bone 
mineralization, and proteins containing gamma carboxyglutamate (Gla), a rare amino 
acid whose only known function is to bind calcium (9). Also, cells that are known to be 
capable of osteoblastic differentiation and which may be the predecessors of vascular 
calcifying cells are found in atherosclerotic plaques (9). Though calcification does define 
a plaque as being advanced and complicated, the presence of calcification in itself does 
not predispose to complications of atherosclerosis. In fact, some studies suggest that 
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calcification of the arteries due to atherosclerosis, though a useful marker of 
atherosclerosis (see below), may actually strengthen a plaque, thus preventing it from 
undergoing complications leading to clinical events (9 13, 14). 
Epidemiology 
The social importance of arteriosclerosis is well known, and can be defined by 
examining the epidemiological and health-care cost data available. All atherosclerotic 
cardiovascular disease was estimated to account for $259 billion dollars of health care 
costs in 1997, up from $210 billion dollars in 1993. The biggest portion of this amount 
consisted of $51 billion dollars for coronary heart disease alone, followed by $35.5 
billion dollars for congestive heart failure and $19 billion dollars for stroke (4). In 2002, 
the estimated direct costs of major atherosclerotic disease, consisting of coronary heart 
disease, stroke, and congestive heart failure, are $110.4 billion dollars. This estimate 
does not include the indirect costs of these diseases from lost productivity and does not 
include other atherosclerotic diseases such as lower extremity gangrene (15). 
The clinical importance of arteriosclerosis is evident when examining the 
epidemiological data on the prevalence and associated mortality and morbidity of 
atherosclerosis. Although atherosclerosis is a diffuse process capable of involving any 
vascular territory in the body, symptomatic atherosclerotic disease most often involves 
the heart, brain, kidneys, lower extremities and intestines. For this reason, data about 
incidence and prevalence of atherosclerotic disease are generally expressed in reference 
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to ischemic coronary heart disease (CHD) and its consequences (e.g., angina, myocardial 
infarction, congestive heart failure), cerebrovascular accidents (CVA), end organ 
infarction and ischemia, and gangrene of the limbs (2). Atherosclerotic disease and its 
clinical consequences account for over half of all deaths in the developed world (2), and 
have been the number one killer in the United States since 1900 (15). Fatty streaks are 
nearly ubiquitous, with one study demonstrating that all teenagers in the United States 
who were sampled had fatty streaks somewhere in their arterial system (16). The 
prevalence of more advanced atherosclerosis increases as the patient ages, with 
atherosclerotic plaque present in 50% of individuals aged 20-29 years but in 80% of 
individuals aged 30-39 (9). Although on the decline in recent years due to prevention and 
advances in medical care, coronary heart disease (CHD) independently remains the 
leading cause of death in the United States (2, 17-19). Approximately 12 million people 
in the United States have CHD (Figure 3), resulting in over 500,000 deaths per year (4, 
15, 18,20). 
Figure 3 (on following page). Prevalence of coronary heart disease by age and sex 
(United States: 1988-1994). (Adapted from American Heart Association. 2001. 2002 





Some data do exist for the presence of atherosclerotic calcification in the 
population. Calcification of the vasculature is present in 50% of individuals aged 40 to 
49 years, and 80% of individuals aged 60 to 69 (9). In one study, calcified plaques 
specifically in the thoracic aorta were present in 8.5% of men and 3.9% of women aged 
40 to 44 years, with equalization of the sexes by age 60 and more than 80% in both sexes 
at age 75 to 80 (6,21-22). 
Risk Factors 
Several large prospective clinical trials have identified many risk factors, both 
constitutional and acquired, which contribute to the pathogenesis and evolution of 
atherosclerosis. The major risk factors are described in more detail below and are shown 

in Table 3 along with some minor and uncertain risk factors. Age, sex, family history 
and genetics are the constitutional factors (2, 9, 15). 
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Major Lesser, Uncertain, or Nonquantitated 
Constitutional Obesity 
Increasing age Physical inactivity 
Male gender Stress 
Genetics Homocysteine 
Postmenopausal estrogen deficiency 
Potentially Controllable High carbohydrate intake 
Hyperlipidemia Alcohol 
Hypertension Lipoprotein (a) 
Cigarette smoking Hardened (trans) unsaturated fats 
Diabetes mellitus Chlamydia pneumoniae 
Herpes viruses 
Table 3. Risk factors for atherosclersosis. (Adapted from Schoen F.J., and Cotran R.S. 
1999. Blood vessels. In Robbins Pathologic Basis of Disease. R. Cotran, V. Kumar, and 
T. Collins, editors. Philadelphia: W.B. Saunders Company. 493-541) 
Probability (%) 
Age (y) Women Men 
30-34 <1 3 
35-39 <1 5 
40-44 2 6 
45-49 5 10 
50-54 8 14 
55-59 12 16 
60-64 13 21 
65-69 9 30 
70-74 12 24 
leart disease based on age and gender. Table 4. Average 10-year risk of coronary 
(Adapted from Kannel, W.B. 1998. Overview of atherosclerosis. Clinical Therapeutics. 
20, Supplement B: B2-B17) 
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As is evident from the description of pathogenesis and molecular biology, 
atherosclerosis begins early in life and becomes progressively worse over the course of 
the lifespan to the point of becoming clinically relevant after middle age. One possible 
mechanism of this correlation may be a decrease in elasticity as the artery ages (8). The 
prevalence of CHD is age-dependent (Table 4), with an increase from 86 per 1000 men at 
ages 45 to 64 up to 169 per 1000 men at ages 65 and older suffering from CHD. These 
numbers in women, though slightly lower, are substantial and on the rise (4). In addition, 
1 in every 3 males and 1 in every 10 females in the United States suffers a major 
atherosclerotic cardiovascular event before the age of 60 years. This risk for these events 
is also age-dependent, with the annual rate increasing from 5 per 1000 in the 35 to 44 age 
range to 59 per 1000 in the 85 to 94 age range (4). An additional example is the five-fold 
increase in the incidence of myocardial infarction from age 40 to age 60 (2). Some of 
these data are presented in a different form in Figure 4. 
Additional data show that the male sex is also an independent factor in the 
prevalence of atherosclerosis (see again. Table 4), though the distinction between sexes 
becomes insignificant after the age of menopause as the occurrence of atherosclerotic 
events accelerates in women (Figure 4). There is some data supporting the idea that this 
trend is due to a favorable lipid profile and better endothelial function associated with 
higher levels of estrogen (2, 9). 
Figure 4 (on following page). The incidence major cardiovascular events in 36-year 
follow-up of the Framingham Study (Reproduced from Kannel, W.B. 1998. Overview 
of atherosclerosis. Clinical Therapeutics. 20, Supplement B: B2-B17) 
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The final constitutional factor is genetics. Familial clustering of atherosclerosis 
certainly exists. The process is likely polygenic, and often linked to other risk factors 
such as diabetes or hypertension. There also exist well-defined familial diseases of lipid 
metabolism leading to hyperlipidemia with and without hypercholesterolemia (2). 
Many of the major risk factors for atherosclerotic disease are acquired or 
controllable with therapy or lifestyle modification. These include hyperlipidemia, 
hypertension, smoking, and diabetes (2, 4, 15, 23-24). It is at the level of these factors 
that the greatest strides have been made in reducing the incidence of atherosclerosis 
related disease over the past several decades with the use of primary and secondary 
prevention (2, 15). 
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Hyperlipidemia is an obvious offender when one analyzes the molecular biology 
of atherosclerosis as described above. The proof for the relationship lies in the high 
incidence of atherosclerotic disease present in high lipid states such as familial 
hypercholesterolemia and diabetes. In addition, it has been proven that the higher the 
level of cholesterol, the greater the severity of atherosclerosis, with an exponential 
increase after exceeding 200mg/dl of total cholesterol. Many studies have also shown 
that a decrease in serum cholesterol with diet and lipid-lowering drugs leads to a decrease 
in atherosclerotic disease (2, 9). 
Hypertension is also a controllable risk factor, and is actually a stronger risk 
factor for atherosclerosis than hypercholesterolemia after age 45 years. Both systolic and 
diastolic pressures are important, and control of blood pressure with antihypertensive 
therapy reduces the incidence of atherosclerotic disease (2). 
Cigarette smoking is a well-established risk factor for both men and women, and 
is believed to have contributed to a recent increase in the incidence of atherosclerosis in 
women (2, 9). As with aging, smoking has been shown to decrease the elasticity of 
arteries, thereby leading to flow changes which may lead to hemodynamic endothelial 
injury (8). Smoking can cause a 200% increase in the death rate from ischemic heart 
disease when one or more packs are smoked per day for several years. This risk is 
partially reversible, as cessation of smoking halves this increase in risk (2). 
The last major risk factor is diabetes mellitus. Diabetes can induce 
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hypercholesterolemia and has been shown to nearly double the risk of myocardial 
infarction as compared to nondiabetics. The most prevalent atherosclerotic disease in 
diabetics is atherosclerosis-induced gangrene of the lower extremities, the risk of which 
is increased by a factor of 100 in diabetics versus nondiabetics (2). 
Many other minor and uncertain risk factors exist, as described in Table 3. One 
important facet of this data is that atherosclerosis can develop in the absence of any 
known or hypothesized risk factor, emphasizing the fact that this field is still actively 
evolving and its true pathogenesis remain highly speculative (2). Another important fact, 
summarized in Figure 5, is that the risk factors are not merely additive when 
compounded. They are somehow synergistic so that two risk factors increase the risk of 
atherosclerotic disease fourfold, while three risk factors increase the risk sevenfold (2). 
70- 
BP Systolic t?G 160 160 160 160 160 160 
Cholesterol 220 220 260 260 260 260 260 
•'. 






Cigarettes ■ II — — + + 
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Figure 5 (on preceding page). Estimated 10-year risk of coronary heart disease 
according to various combinations of risk factor levels. (Reproduced from Schoen F.J., 
and Cotran R.S. 1999. Bloodvessels. In Robbins Pathologic Basis of Disease. R. 
Cotran, V. Kumar, and T. Collins, editors. Philadelphia: W.B. Saunders Company. 493- 
541) 
Imaging 
Imaging of atherosclerosis in vivo is an important method of identifying and 
following patients with atherosclerotic disease. Imaging of the coronary arteries by 
noninvasive means is difficult but possible with certain modalities. Another potential 
target for imaging is the aorta. Many studies demonstrate that atherosclerosis of the aorta 
correlates well, positively and negatively, with the presence of the generalized 
atherosclerotic process (1, 5, 9, 25). This relationship seems especially useful for 
younger patients (6, 26). 
Imaging of atherosclerosis can be accomplished by a variety of modalities. The 
list of modalities continues to grow with the advent of newer technologies and imaging 
techniques such as electron-beam computed tomography (EBCT) and “black-blood” 
magnetic resonance imaging (MRI) (1, 13, 27-28). The primary modalities are 
echocardiography, fluoroscopy, and computed tomography. These modalities, as they 
pertain to this study, will be discussed below. 
Echocardiography, specifically transesophageal echocardiography (TEE), is a 
noninvasive modality ideal for the detection, measurement and characterization of 
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atherosclerotic plaques of the aorta. It is able to detect intimal thickening, often the first 
detectable sign of atherosclerosis, ulceration, and calcification, and has the ability to 
grade plaques based on these characteristics (13, 26, 29). There are limitations of TEE, 
however, for the puiposes of this study. For example, TEE cannot fully visualize the 
ascending aorta and arch due to its anatomic relationship to the trachea (13, 30). TEE can 
also visualize only the proximal coronary circulation with a good degree of resolution, 
and does not provide adequate imaging for the detection of coronary calcium. In 
addition, without advance specification requesting characterization of the aorta, most 
echocardiographers do not focus on obtaining adequate images of the descending aorta. 
Although a versatile tool in the detection of atherosclerosis of the aorta, TEE was not 
considered a useful imaging modality in this retrospective study due to these limitations. 
Fluoroscopy is an excellent imaging modality for the detection of significant 
atherosclerotic disease by its virtue of being able to detect lesions which impinge on the 
lumens of the coronary arteries or the aorta. This modality is also useful in detecting 
moderate to large levels of coronary and aortic calcification, though its sensitivity for 
lesser amounts of calcium is limited (9). In addition, coronary angiography and 
aortography are invasive procedures which not all patients qualify for due to risks 
inherent in the procedure and the use of fluoroscopic dye. For the purposes of this study, 
not all patients in the Marfan group received coronary angiography or aortography. In 




Conventional computed tomography (CT) is extremely useful for the specific 
purpose of detecting vascular calcification (9). The specificity of coronary calcification 
seen on CT for significant coronary artery disease are 78% to 100% in studies comparing 
CT to angiographically significant stenosis, with a positive predictive value of 83% to 
100%, suggesting that if coronary calcium was seen on CT, significant coronary artery 
disease was likely to be present (9). In addition, computed tomography is also useful in 
assessing the entire thoracic aorta, allowing for even better sensitivity and specificity for 
significant atherosclerotic disease (9, 13). Some studies suggest that the presence of 
atherosclerotic lesions in the thoracic aorta possesses both a strong positive predictive 
value and a high negative predictive value (as high as 79% in one study) for coronary 
artery disease, suggesting that noninvasive detection of aortic atherosclerosis is a useful 
and reliable marker for significant atherosclerotic disease in the patient (5, 25). Electron 
beam CT, a novel technique which allows for very exact quantification of coronary 
calcium, is extremely useful for assessing the degree of atherosclerotic disease (1,9, 13). 
This new technique, however, is not universally available and is too recent to be available 
for this retrospective study. Conventional CT, however, is universal and has been used in 
assessing the severity of atherosclerotic disease by use of a semi-quantitative calcification 
grading scale which correlates well with the exact quantification of electron beam CT (1, 
10, 22, 30-32). This can be accomplished within the coronary arteries, and more so 
within the aorta, the larger size of which makes it an easier subject of imaging. CT is 
also useful for the purposes of this study because many Marfan patients are followed with 
serial CT scans for assessment of aortic aneurysm growth (see details of Marfan and 
quantitative method below). 
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Calcification of vessels has been shown to be a definite marker of atherosclerotic 
disease. Detection of atherosclerosis of the coronary arteries and aorta via identification 
of calcification within these arteries is a reliable indicator of presence and severity of 
atherosclerotic disease (9, 14). For example, calcification of the coronary arteries occurs 
exclusively in atherosclerotic arteries, sparing normal vessels (9). Thus, calcification of 
the aorta and coronary arteries, visualized with CT, is a marker for atherosclerosis of 
these vessels. In addition, atherosclerosis of the aorta itself is a significant marker for 
coronary artery disease (1, 27, 33-37). To extend this relation farther, since 
atherosclerosis is a diffuse process, the calcification of these vessels is also an indicator 
of generalized atherosclerotic disease (1,9). Since the aorta and coronary arteries are 
among the most frequently affected vessels, as described above, their use as markers for 
atherosclerotic disease is also extremely sensitive. In addition, this relationship is most 
significant when studying patients younger than 65 years of age (6, 26, 34). Calcification 
of the coronary arteries and aorta is thus ideal for the study of the relatively young 
Marfan patient population in this study. 
Background on the Marfan Syndrome 
Definition 
First described in 1896 by the Parisian pediatrician Auguste Marfan, the Marfan 
syndrome has become a prototypical example of the group of syndromes collectively 
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known as the disorders of connective tissue. Marfan syndrome (MFS), with an incidence 
of approximately 1 in 10,000 to 20,000 live births and a prevalence of 1 in 3,000 to 5,000 
individuals, is an autosomal dominant condition caused by mutations in the FBN1 gene 
encoding the extracellular molecule fibrillin-1 (38-43). The lifespan of patients with 
MFS has increased steadily over the past decades as treatment modalities evolve. In 
1972, the average lifespan for a patient with MFS was 32 years. This number increased 
to 41 years in 1993 and 61 years in 1996, and now approaches the normal lifespan of the 
population. For as yet unknown reasons, the lifespan of patients with MFS is 
significantly lower in men than in women (38, 41, 43-44). 
Features and Diagnosis 
MFS lies at the extreme end of a spectrum of disease conditions, the 
fibrillinopathies, ranging from variations of normal to individual features of MFS to MFS 
(41, 44). MFS is a pleiotropic disease involving abnormalities in multiple organ systems, 
most notably the ocular, musculoskeletal, and cardiovascular systems (38, 39, 41, 44). 
The diagnostic criteria for MFS were recently updated by the group from Gent, Belgium 
(39), and are listed in Table 5, while the differential diagnoses of MFS are listed in Table 
6. The classic, diagnostic features of MFS and some of their treatments are described 
here, with particular emphasis on the cardiovascular manifestations of the disease. In this 
revised scheme, “major” criteria are those which carry high specificity for MFS due to 
relatively low frequency in other conditions and the general population (39). 
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Ocular manifestations of MFS include ectopia lentis, with upward dislocation of 
the lens unilaterally or bilaterally, myopia secondary to the increased length of the globe 
and flattening of the cornea, retinal tears and detachment, and glaucoma (38-39, 41-42). 
Dislocation of the lens, one of the most recognized ocular abnormalities of MFS, occurs 
in approximately 60% of patients with the disease. Conservative correction of vision 
with ectopia lentis in MFS is usually attempted prior to surgical correction with lens 
removal and replacement. Though a major diagnostic manifestation of MFS, ectopia 
lentis does occur as an isolated disease in some patients with FBN1 mutations who do not 
meet diagnostic criteria for MFS (38, 41). This underscores the importance of the Gent 
criteria and will be discussed in more detail in the section on molecular biology and 
genetics. 
Ma|or criteria Minor criteria Involvement 
family history f urst-degree relative who meets diagnostic criteria 
.Warfan-caosing FBN 1 mutation 
Haplofype around F&F4! associated with 
confirmed Marfan inherited by descent 
None Major Criterion must be met 
or family history is 
TOTOontributoiy 
Skeletal Presence erf any four of the following: 
Pectus carirtatum 
Pectus excavratwo requiring surgery 
Reduced upper segment-lower segntertt ratio 
0# sparulseight >1.05 
Positive wrist and thumb signs 
Scoliosis >20 degrees or spondyloWshesis 
Extension <170 degrees at elbow 
Medial displacement of the medial malleolus 




High arched palate with dental 
crowding 
facial appearance 
1 wo of the components of the 
major criteria or me of the 
components of the major 
criteria and two minor criteria 
Ocular Ectcpla lentis fiat cornea dry ketatometryi 
increased globe length (by ultrasounds 
Hypoplastic iris or hypoplastic ciliary 
muscle causing decreased miosis 
Two minor Criteria 
Cardiovascular Dilation of die ascending aorta with or with¬ 
out aortic regurgitation involving at least the 
sinuses ui Valsalva 
Dissection of the ascending aorta 
Mitral valve prolapse with or without 
mitral regurgitation 
Dilation of main pulmonary artery 
without other cause at age 40 years 
or younger 
Calcification of the mitral annulus at 
age 40 years or younger 
Dilation or dissection of she descend¬ 
ing thoracic or abdominal aorta at 
age 50 years or younger 
One major or one minor 
criterion 
Pulmonary Koto Spontaneous pneumothorax 
Apical Webs {radiographically) 
One minor criterion 
SWn and central 
nervous system 
Lumbosacral dural ectasia Striae atrophicae not associated with 
marked weight changes, pregnancy; 
or repetitive stress 
Recurrent or incisional hernia© 
One major or one minor 
criterion 
*To make a d&tgnas-lt of Marfan syndrome in an sffcfcvkftual no family hlssory requires major* crisers in two organ systems Involvemerw of a ?hird. \i there it 
a family history, major criteria must be met >n one organ system and another musl be Involved. 
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Table 5 (on preceding page). Diagnostic criteria for the Marfan syndrome according to 
the revised 1996 Gent criteria. (Reproduced from Wright M.J., and Dietz, H.C. 1999. 
Heritable disorders of connective tissue. In Oski’s Pediatrics: Principles and Practice. 
J.A. Mcmillan, C.D. DeAngelis, R.D. Feigin, and J.B. Warshaw, editors. Philadelphia: 
Lippincott Williams & Wilkins. 1892-1899) 
Common Skeletal Manifestations 
Classic Ehlers-Danlos syndrome (MTM 130000, 130010, 130020) 
Sickle-cell disease (M1M 141900.0243) 
Multiple endocrine neoplasia type III (MIM 162300) 
Trisomy 8 
Kline fe 1 ter s y n drome 
Congenital contraetural arachnodactylv (MIM 121050) 
Common Ocular Findings 
Ehlers-Danlos syndrome, kyphoscoliosis form (type VI; MIM 225400)—retinal detachment 
Wcill-Marchcsani syndrome (MIM 277600)—ectopia Icntis 
Autosomal dominant ectopia lends (MIM 129600) 
Autosomal recessive ectopia lends with (MIM 225200) and without (MIM 225100) ectopic 
pupils 
Common Cardiovascular Features 
Mitral valve prolapse 
MASS phenotype (familial mitral valve prolapse; MIM 157700). 
Dilatation of the ascending aorta 
Tertiary syphilis 
Ankylosingspondy litis 
Rel apsing polychondriti s 
Reiter syndrome 
Familial aortic aneurysm (MIM 132900) 
Bicuspid aortic valve, coarctation of the aorta, and medial degeneration of the ascending aorta 
Table 6. The differential diagnosis of Marfan syndrome. (Reproduced from Pyeritz R.E. 
2000. The Marfan syndrome. Annual Review of Medicine. 51:481-510) 
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The main musculoskeletal features of MFS are arachnodactyly, confirmed by the 
thumb and wrist signs, tall stature with decreased upper body to lower body ratio and arm 
span exceeding height, generalized joint hypermobility, protrusio acetabuli, and disorders 
of tubular bone overgrowth, manifest as scoliosis and pectus deformities (38-39, 41-42, 
44). Since many of these musculoskeletal features are common in the population, a 
combination of multiple defects is required for involvement of this system (39). A 
positive thumb sign for arachnodactyly means that the distal phalanx or entire fingernail 
of the thumb protrudes beyond the fifth digit when the fist is clenched. A positive wrist 
sign means that the thumb and fifth digit overlap when circling the contralateral wrist. 
Scoliosis and pectus deformities may require surgical correction if the subsequent 
restrictive pulmonary disease and cor pulmonale is morbid, but these corrections must be 
timed to avoid recurrence due to continued bone growth (41-42). 
The main cardiovascular features of MFS are aneurysmal aortic dilatation, with 
and without aortic regurgitation, aortic dissection and/or rupture, and mitral valve 
prolapse (38-39, 41, 44). Prior to the development of successful surgical intervention, 
these cardiovascular features accounted for over 90% of mortality in MFS (41-42). 
Dilatation of the aorta is found in 50% of children with MFS, and progresses with time to 
involve 60% to 80% of adults. Many patients have involvement of other segments of the 
aorta (38, 43). In addition, other arteries, including the pulmonary artery, the carotids, 
and cerebral vessels may display dilatation (38). Aortic dissections occur more 
frequently as the aorta becomes progressively more dilated, with the majority being Type 
A dissections originating at the aortic root (38, 44). 
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Mitral valve prolapse is also common in MFS, but due to its high prevalence as an 
isolated entity, it is only a minor criterion for MFS. In MFS, mitral valve prolapse occurs 
with higher incidence in women and with age (38). The cause of mitral valve prolapse in 
MFS, as with isolated mitral valve prolapse, seems to be a redundancy of the valve 
leaflets with dilatation of the mitral annulus and stretching of the chordae tendinae. In 
addition, the annulus in these patients is often calcified (38, 41); this fact is particularly 
relevant to the present study in demonstrating that patients with MFS do seem to have 
normal, active calcification of damaged endothelial and vascular structures. 
The management of aortic disease in patients with MFS has progressed 
dramatically in the past few decades with the development of composite graft 
replacement surgery of the aortic valve and ascending aorta and the demonstration of a 
potential prophylactic benefit with the use of beta-blockers and possibly calcium channel 
antagonists. (38, 41, 43-44). Elective repair of the aortic root, when the root diameter 
exceeds twice the upper limit of normal for an individual’s body surface area, is optimal 
(38, 41-42). The 30-day mortality for elective repair is significantly lower as compared 
to the urgent (within 1 week of surgical consultation) and emergent repairs (within 24 
hours of surgical consultation) which occur as a result of dissection or impending 
dissection (38, 41, 45). In addition, the likelihood of requiring additional aortic surgery 
at other sites in the aorta is increased in patients who have a dissection at the time of their 
first surgery (38, 45). These statistics are especially important for the management of 
pregnant MFS patients, who are at increased risk for acute enlargement of the aortic root 
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diameter and dissection (38, 44). Also, as treatment for the cardiovascular manifestations 
of MFS are improving, the resultant increase in lifespan has important implications for 
the more prominent role of manifestations in the other organ systems involved. In the 
case of mitral valve prolapse, mitral valve repair or replacement is often required if heart 
failure occurs (41). Another important point in the management of the cardiovascular 
features of MFS is antibiotic prophylaxis during procedures which may introduce 
bacteria into the bloodstream, as these patients are particularly prone to bacterial 
endocarditis (41). 
Other features of MFS include dural ectasia, cutaneous striae densae, and apical 
pulmonary blebs with spontaneous pneumothorax (39). The dural ectasia, resulting in 
enlargement of the lumbosacral spinal canal with erosion of vertebral bone and potential 
meningoceles, occurs in up to 90% of MFS patients but has an uncertain clinical 
significance beyond minor nerve compression symptoms (38-39). The cutaneous striae 
occur in flexural areas and can often be associated with incisional and inguinal hernias 
(38-39). 
Table 5 details which of these features qualify as minor and major diagnostic 
criteria for NTFS, as well as the requirements for involvement of an organ system. To 
achieve an independent diagnosis of Marfan Syndrome by these 1996 Gent criteria (39), a 
patient must have major manifestations in two systems with involvement of a third 
system. To qualify for a major criterion in the family history or genetic history category, 
a patient must have a parent, sibling, or child meeting the independent criteria, or they 
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must possess a mutation in FBN1 known to cause MFS, or they must possess a linked 
haplotype around the FBN1 gene which is known to be associated with independently 
diagnosed MFS in the family. If a patient has one of these major criteria in the family 
history category, then he or she may be diagnosed with MFS if they have a major 
manifestation in one system with involvement of a second system. The simple presence 
of a mutation in the FBN1 gene is not sufficient for diagnosis due to the wide variation in 
phenotype from such mutations. This will be discussed in greater detail below. 
Molecular Biology and Genetics 
The FBN1 gene, now linked to MFS and other similar disease processes, produces 
fibrillin-1, a glycoprotein component of the connective tissue lOnm elastin-associated 
microfibril (44). Another fibrillin gene, FBN2, and its product fibrillin-2, have also been 
identified and linked to congenital contractural arachnodactyly, but not to MFS (41). 
FBN1 is a large gene with 65 exons located at chromosome 15q21.1. Fibrillin-1 and the 
connective tissue microfibril are components of both elastic and nonelastic connective 
tissues and are essential to normal elastic fibnllogenesis. With many cysteine-rich 
sequences, fibrillin-1 is homologous to epidermal growth factor or transforming growth 
factor-beta binding protein-1 (38, 46). 
There is extensive intragenic heterogeneity, with over 100 mutations in 
FBN1 identified in patients with MFS. In addition, many other mutations have been 
identified in patients with milder phenotypes that overlap with MFS. Also, at least 25% 
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of patients with MFS represent new mutations not present in the family genetic history 
(38, 41). These facts make molecular diagnosis of MFS extremely difficult, so that the 
clinical diagnostic criteria mentioned above are more precise and still necessary despite 
knowledge of the molecular biology of the disease (41-42, 44, 47). In mutations known 
to cause MFS, penetrance approaches 100% but wide clinical variation (39, 41, 43-44, 
47). Though no exact genotype to phenotype correlations have been defined within MFS, 
it seems that patients with exon skipping or in-frame mutations have a more severe 
phenotype than do patients with termination mutations (38, 41, 44). This fact is 
consistent with the thought that the MFS phenotype is the result of a dominant negative 
action of the mutant fibrillin-1 protein (41). 
The connective tissue microfibrils are ubiquitous, and act as principal 
components of elastic fibers, anchoring fibers between the dermis and epidermis, and as 
the ocular zonules (41,47). In the arterial wall, the changes are mainly in the media. The 
media of the elastic arteries in patients with MFS display fragmentation and disarray of 
the elastic fibers, a decreased amount of smooth muscle cells, and the separation of 
muscle fibers by collagen and mucopolysaccharide (41-42). The result of these defects 
is increased stiffness and decreased distensibility in the ascending aorta (38, 41, 43). 
Arteriosclerosis in the Marfan Syndrome 
Very little literature exists regarding the prevalence of arteriosclerosis in patients 
with MFS. An extensive literature search using the Medline database revealed no journal 
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entries focusing on both Marfan syndrome and arteriosclerosis. One study does find that 
the rate of coronary artery disease detected by coronary angiography was significantly 
less in patients with acute aortic dissection than in patients with abdominal aortic 
aneurysms or arteriosclerosis obliterans, with a rate of 19.7%, 43.9%, and 51.5%, 
respectively (48). This study, however, specifically excluded patients with the Marfan 
syndrome, thus making difficult any extrapolation to this particular subset of patients 
with acute aortic dissections. The experience of the cardiothoracic surgery group at Yale, 
however, suggests that patients with MFS do have significantly less arteriosclerotic 
disease in their large arteries than do other patients. 
Many mechanisms could provide a reason for this observation. The reason could 
be a simple age bias, since the operative MFS population tends to be younger than other 
cardiothoracic surgery patients. There could be reasons why disruption of the normal 
arterial media could provide protection from intimal injury or progression of intimal 
lesions. As mentioned above, the defective fibrillin-1 protein is an integral component of 
the lOnm connective tissue microfibril. This microfibril interacts with many different 
constituents of the extracellular matrix and a defect in the fibril could create difficulties in 
the normal inflammatory processes required for arteriosclerosis. For example, loss of the 
normal elastic properties of the artery could prevent normal hemodynamic stresses which 
cause endothelial injury. This would seem paradoxical, however, due to the increase in 
atherosclerosis which occurs with age due, theoretically, to the decreased elasticity of 
older vessels. Also, there could be as yet unknown functions of the microfibril, perhaps 
in interactions with the thrombotic mechanism or serum lipoproteins, which could link a 
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defect in this microfibril to the process of arteriosclerosis. Alternatively, as mentioned 
above, there is a decrease in the number of smooth muscle cells in the arterial media of 
patients with MFS. Without these smooth muscle cells, normal progression of the 
atherosclerotic plaque could not occur. They could not migrate to the intima (due to 
decreased number as well as potentially defective migratory properties in the setting of 
defective microfibrils) and elaborate the extracellular matrix and intercellular mediators 
which build upon the early lesion. 
The dearth of knowledge in this area creates an opportunity for ground level 
research. It is the aim of this study to probe the relationship between Marfan syndrome 
and arteriosclerosis. The specific hypothesis and aims of the study are given below. 
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Statement of Purpose 
No organized and decisive studies evaluating the relationship between the Marfan 
syndrome and arteriosclerosis exist in the medical literature. Nevertheless, the Marfan 
syndrome is a disease of the connective tissue of the vessel wall, placing it in a unique 
position to interact extensively and by a variety of means with the processes of 
arteriosclerosis. It is the observational experience of the faculty of the section of 
cardiothoracic surgery at Yale University School of Medicine that patients with Marfan 
syndrome who have been operated upon at Yale-New Haven Hospital have had relatively 
low rates of overt arteriosclerosis. 
This pilot study has been designed to probe the nature of the relationship between 
these two important diseases in order to 1) determine the prevalence of arteriosclerosis in 
the Marfan syndrome, 2) compare patients with the Marfan syndrome to the general 
population in this regard, and 3) begin to understand any lessons each disease may offer 
about the other. In time, this work will be developed into a national study with a large 
cohort of patients. The hypothesis of this study is that patients with the Marfan syndrome 
have significantly less arteriosclerotic disease, as detected by calcification in the thoracic 




Institutional Review Board Approval 
Approval for this study was obtained from the Human Investigation Committee of 
the Yale University School of Medicine prior to the initiation of the study. 
Selection of Patients 
The database of the Yale Center for Thoracic Aortic Disease was used to select 
patients for the Marfan arm of the study. The database contains 1282 patients with aortic 
disease who have been cared for by the section of cardiothoracic surgery at Yale 
University School of Medicine. Of these patients, 65 carried a confirmed diagnosis of 
Marfan syndrome using the Gent diagnostic criteria. These 65 patients were then cross- 
referenced with the databases of the department of diagnostic imaging for the availability 
of a pre-operative CT scan of the chest without the use of intravenous contrast, resulting 
in a total of 8 patients in the Marfan arm. Only pre-operative scans were included in this 
study due to concerns about artifact from prosthetic grafts and changes in flow dynamics 
which may affect local vessel injury. 
For the control arm of the study, the databases of the department of diagnostic 
imaging were queried for patients between September, 1998, and February, 1999, and 
between September and December, 2000, who had undergone chest CT scanning without 
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the use of intravenous contrast. Patients with definite cardiac or aortic pathology were 
excluded, as were patients who had undergone prior thoracic surgery. These patients 
were then matched with the patients in the Marfan arm of the study for both age at time 
of CT scanning and gender. Age matching was conducted by creating categorical ranges 
of age as follows: < 30 years old, 31-35 years old, 36-40 years old, and 41-45 years old. 
This resulted in 8 control patients. 
Evaluation of CT scans 
All CT scans were officially interpreted on film or AutoRad by Dr. Coralie Shaw 
from the department of diagnostic imaging. The scans were evaluated for the presence of 
calcification within the walls of the coronary arteries or the thoracic aorta. The right 
coronary artery, left circumflex artery, and the left anterior descending artery were 
evaluated separately, with the sum of their individual scores forming the score for the 
coronary arteries. Points for calcification were given as follows: 0 points for no calcium, 
1 point for minimal flecks (clmm diameter) of calcium on single levels, 2 points for 
more than three minimal flecks or larger non-circumferential flecks (l-3mm diameter) on 
single or multiple levels, and 3 points for severe (>3mm diameter) flecks or 
circumferential calcification. This semi-quantitative scale for calcification has been 
described by others (1, 10, 22, 30-31). The total scores possible were 3 points for the 
thoracic aorta and 9 points for the coronary arteries (3 from each artery). 
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Review of Medical History 
The hospital charts of all included patients were thoroughly reviewed for the 
presence of the risk factors discussed above which may have confounded the analysis of 
arteriosclerosis. Age and gender had already been matched in creating the control arm. 
The factors for which the charts were searched include the body mass index (weight in 
kilograms divided by height in meters squared) at the time of scanning, as well as history 
of hypertension, diabetes mellitus, smoking, and hypercholesterolemia. History of prior 
myocardial infarction or stroke was also included in the chart review. History of 
hypertension was considered present if the patient had chart documented history of 
hypertension at the time of scanning, was taking antihypertensive medication at the time 
of scanning, or had a chart documented blood pressure above 140 millimeters of mercury 
systolic or 90 millimeters of mercury diastolic on at least two separate occasions (31). 
History of diabetes mellitus (DM) was considered present if the patient had chart- 
documented history of DM at the time of scanning or was taking insulin or oral 
hypoglycemic medication at the time of scanning. History of smoking was considered 
present if the patient had chart documented history of current or remote smoking at the 
time of scanning. History of hypercholesterolemia was considered present if the patient 
had chart documented history of hypercholesterolemia at the time of scanning, was taking 
lipid lowering medication at the time of scanning, or had chart documented total 
cholesterol above 200 milligrams per deciliter on two fasting serum samples (25). 
History of prior myocardial infarction or stroke was considered present if the patient had 
chart documented history of these prior events at the time of scanning. 
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Data Analysis and Statistical Considerations 
The data from the review of patient records and the evaluation of CT scans were 
analyzed for significant differences between the two groups. Continuous variables, 
including average age, average body mass index, average calcification score in the 
thoracic aorta, and average calcification score in the coronary arteries, were evaluated 
using the student’s t-test. Since the number of records was relatively small, the 
dichotomous variables, which included all other confounders from the patients’ records, 
were analyzed using the Fisher exact probability test rather than the Chi-square method. 
In all variables, there was one degree of freedom and differences were considered 
significant at a p-value less than 0.05. As the number of patients studied in this pilot 
study was small, no attempt at multivariate analysis was conducted to determine and 




The results of the record review and CT scan evaluation are given as a 
compilation of the different patients into averages and total numbers with statistical 
results in Table 7. In addition, the data for each patient in each group is given 
individually in Table 8. 
With regard to confounding factors, age and gender were matched in creating the 
control group. However, the average age in the two groups did differ, with the Marfan 
group average at 26.6 years and the control group average at 30.5 years. This difference 
was not significant (t = 0.850, p = 0.55). For all other confounders, the differences 
between the two groups also did not reach statistical significance. The average body 
mass index was 21.9 kg/m2 for Marfan patients and 25.6 kg/m2 for control patients (t = 
1.02, p = 0.49). There were no patients with hypercholesterolemia or prior myocardial 
infarction in either group. Five patients (62.5%) in the Marfan group qualified for 
hypertension while only three (37.5%) qualified in the control group (Fisher probability = 
0.24). All five of the Marfan patients, however, qualified in this category due to beta- 
blocker therapy for aortic dissection prophylaxis, not for classically defined hypertension. 
In contrast, all three of the control patients qualified in this category due to chart- 
documented elevations in blood pressure in addition to anti-hypertensive therapy. No 
patients (0%) had chart-documented diabetes mellitus in the Marfan group, while three 
patients (37.5%) had diabetes mellitus in the control group (Fisher probability = 0.1). 
Four patients (50%) in the Marfan group and three patients (37.5%) in the control group 
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had a history of cigarette smoking (Fisher probability = 0.34). Finally, one patient 
(12.5%) in the Marfan group, but no patients (0%) in the control group, had a history of a 
minor prior stroke (Fisher probability - 0.5). 
The evaluation of CT scans revealed only one patient in the study who had 
evident calcification in the thoracic aorta and/or coronary arteries. This control patient 
received a calcification score of 1 point for the thoracic aorta and 1 point for the left 
anterior descending artery (the left circumflex artery and the right coronary artery were 
without calcification). This resulted in an average calcification score of 0.125 for the 
control group and an average calcification score of zero for the Marfan group in both the 
thoracic aorta and the coronary arteries. These differences were analyzed with the 
student’s t-test and found to be not significant, with a p-value of 0.5 in both vessel 
distributions. 
Age BMI HTN Choi. DM Smoker MI CVA Coronaries Aorta 
Marfan 26.6 21.9 5 0 0 4 0 1 0 0 
Control 30.5 25.6 3 0 3 3 0 0 0.125 0.125 
p-value 0.55 0.49 0.24 N/A 0.1 0.34 N/A 0.5 0.5 0.5 
Table 7. Compilation of results for the confounding factors and calcification scores for 
each group with results of analysis for statistical analysis. (Abbreviations: Age=average 
age at time of CT scan, BMI=average body mass index in kg/m2, HTN=number of 
patients with history of hypertension, Chol.=number of patients with history of 
hypercholesterolemia, DM=number of patients with history of diabetes mellitus, 
Smoker=number of patients with history of cigarette smoking, MI=number of patients 
with history of prior myocardial infarction, CVA=number of patients with history of prior 
stroke, Coronaries=average calcification score in the coronary arteries, Aorta=average 
calcification score in the aorta, p-value=Fisher probability for F1TN, DM, Smoker, and 




Patient Gender Age BMI HTN Choi. DM Smoker MI CVA Coronaries Aorta 
1 M 18 15.6 + - + - - 0 0 
2 M 32 19.4 + - - - - 0 0 
3 M 17 19.3 + - - - - 0 0 
4 M 36 29.8 + - - - + 0 0 
5 F 42 22.7 - - + - - 0 0 
6 F 19 18.0 - - - - - 0 0 
7 F 25 23.1 - - + - - 0 0 
8 F 24 27.5 + - + - - 0 0 
Control Group 
Patient Gender Age BMI HTN Choi. DM Smoker MI CVA Coronaries Aorta 
1 M 23 20.2 - - + - - 0 0 
2 M 32 22.3 - - - - - 0 0 
3 M 16 15.8 - - - - - 0 0 
4 M 40 41.8 + - - - - 0 0 
5 F 45 18.6 + + + - - 1 1 
6 F 28 24.5 + + - - - 0 0 
7 F 30 36.6 - + + - - 0 0 
8 F 30 25.2 - - - - - 0 0 
Table 8. Results of study for individual patients in each group. (Abbreviations: 
Age=age at time of CT scan, BMI=body mass index in kg/m2, HTN=history of 
hypertension, Chol.=history of hypercholesterolemia, DM=history of diabetes mellitus, 
Smoker=history of cigarette smoking, MI=history of prior myocardial infarction, 
CVA=history of prior stroke, Coronaries=calcification score in the coronary arteries, 





The results of this study indicate that the Marfan and control groups were not 
significantly different in their exposure to the major known risk factors for 
arteriosclerosis. The difference in the average levels of CT-detected calcification in the 
thoracic aorta and coronary arteries of the patients in these two groups also did not reach 
statistical significance. Thus, despite the overwhelming observational trends which led to 
the inception of this pilot study, the data from this study do not support the hypothesis 
that there is a lower level of arteriosclerosis in patients with Marfan syndrome than in the 
general population. 
However, this lack of conclusive support for the hypothesis does not indicate that 
the hypothesis is false. With only eight patients eligible for each group, this pilot study 
has a limited data set which lacks the power to allow for substantial and conclusive 
determinations of scientific significance. The small data set creates difficulty in making 
valid conclusions for several reasons. 
One reason is that the control group cannot be completely matched with the study 
group in regards to the confounding factors. Although the statistical analysis revealed an 
insignificant difference between the groups for each of the confounding factors, the lack 
of power of the analysis could preclude the identification of important differences which 
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may affect the occurrence of calcification in the patients. For example, there are potential 
trends in the data which indicate that the patients with Marfan syndrome are younger, 
thinner, and less likely to have diabetes mellitus than available controls. Though the 
numbers are not significant, the trend is convincing relative to the number of patients in 
the study, and could be a potential source for bias in the observations which served as the 
impetus for this study. These trends could also potentially become significant with larger 
numbers of patients. Also, though the number of patients who qualify as having a history 
of hypertension is larger in the Marfan group, in all cases these patients were on beta- 
blocker therapy for prevention of aortic dissection. In fact, this risk factor, as defined by 
this study and others, may actually be atheroprotective due to the potentially lower blood 
pressures of the patients on beta-blocker prophylaxis without classically defined 
hypertension. 
In addition, only one patient in the study actually had detectable aortic or 
coronary calcification on the CT scan. This patient was the oldest patient included in the 
study and, as an individual, had several of the risk factors for arteriosclerosis (see Patient 
5 under Control Group in Table 8). This fact raises many questions about arterial 
calcification. The data presented above from other studies regarding the prevalence of 
arterial calcification suggest that more of the patients in this study should have had 
calcification present on CT scanning. 
One plausible explanation for the lack of results in this study is the young age of 
the included patients. With average ages of 26.6 years and 30.5 years in the Marfan and 
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control groups, respectively, the population studied may be too young to detect a 
substantial amount of calcification. This limitation may be overcome by including older 
patients. The difficulty with inclusion of older patients lies in the fact that most Marfan 
patients receive operative management of their aortic aneurysms prior to reaching middle 
age. In this case, it may be possible to assess post-operative CT scans of Marfan patients 
at an older age, with age-matched control subjects, by evaluating calcification in areas of 
the aorta and coronary arteries not affected by post-operative changes and artifacts. The 
use of post-operative scans would also drastically increase the numbers of patients 
studied, since many of the 65 Marfan patients were ineligible for this study due to the 
lack of availability of a pre-operative CT scan. This possibility will be discussed in more 
detail below in the section on future directions. 
Another plausible explanation for the lack of calcification seen in this study is that 
a trend is present which is not statistically significant without a larger data set. The 
potential does exist that the hypothesis of this study is accurate, and will be proven to be 
accurate, with larger, more in-depth studies in the future. The consequences of this 
potential finding are remarkable. Arteriosclerosis continues to be a devastating disease 
with global epidemiological impact. Any further understanding about arteriosclerosis 
that could be gained through knowledge of the interaction of the Marfan vasculature with 
the atherosclerotic process would provide great insight into the pathogenesis and 
molecular biology of this important disease. This insight could have direct benefits by 
providing specific molecular targets for therapy and prevention. In addition, as patients 
with Marfan syndrome now survive longer, with nearly normal lifespans, understanding 
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of the impact of arteriosclerosis in these patients is becoming paramount. Also, the 
possibility that the Marfan syndrome may be atheroprotective has significant 
consequences, both in the understanding of arteriosclerosis and in the potential 
psychological benefit this finding could provide to patients with the Marfan syndrome. 
Future Directions 
The limitations of this study provide insight into the potential for future studies, 
which may further this research and allow for more meaningful conclusions about the 
nature of the relationship between Marfan syndrome and arteriosclerosis. Extensions of 
this study have already begun here at Yale. Marfan patients with post-operative films are 
also being included, in order to increase the sample size and evaluate older patients in 
whom arteriosclerosis may be more detectable. It is probable that these scans will be 
useful for the evaluation of calcification and arteriosclerosis despite potential artifact and 
flow disturbances. In addition, with the assistance of advertisement through the 
publications and website of the National Marfan Foundation, a national pool of Marfan 
patients is being recruited for the Arteriosclerosis in Marfan Syndrome (AIMS) study, 
which will possess a much larger set of patients from a variety of locations throughout 
the United States. It is the hope of the authors that, with the results of these larger 
studies, relevant information will be discovered which will provide insight into the 
arteriosclerotic process in Marfan patients, provide an important advance in the 
knowledge of Marfan syndrome, and help to further the journey towards complete 
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